Compare BridgeBio Pharma Inc (BBIO) vs Five Below Inc (FIVE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Five Below Inc — how do they compare? BridgeBio Pharma Inc trades at $82.33 (market cap $16.46B), while Five Below Inc trades at $193 (market cap $10.68B). The key difference: BridgeBio Pharma Inc is the larger of the two by market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Five Below Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | FIVE | |
|---|---|---|
Market Cap | $16.46B | $10.68B |
Sector | Health | Consumer Staples |
52-Week High | $90.17 | $247.71 |
52-Week Low | $44.81 | $131.94 |
Enterprise Value | $18.02B | $11.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Five Below (FIVE) trades at $191.53, up 1.13% on the day, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 21.13% ROE and 8.67% net margin, supported by revenue growth from $3.6B in 2024 to $3.9B in 2025. Recent milestones include opening its 2,000th store and leadership appointments, driving positive media coverage.
The outlook remains positive with a $252.09 analyst price target implying 31% upside, though risks include volatile cash flows and competitive pressures. Earnings momentum and digital marketing investments position FIVE for growth, but investors should monitor execution against 2026's $5.1B revenue target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →
